Needham Reiterates Buy on Cellebrite DI, Maintains $7 Price Target

Benzinga · 05/11/2023 08:11
Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:CLBT) with a Buy and maintains $7 price target.